Shaun Grady has global responsibility for Business Development Operations at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including licensing and partnering, M&A, externalisation and divestments.
Shaun was appointed to his current role in 2013. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010 – 13) and Vice President, Corporate Business Development (2006 – 10).
Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca Group PLC.
Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT) and later MedImmune and led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AstraZeneca – BMS Diabetes Alliance. More recently Shaun led the transaction team for AstraZeneca’s global ADC collaboration with Daiichi Sankyo for DS 8201.
Shaun has led AstraZeneca’s recent externalisation and divestment programme involving transactions with Aspen, Grunenthal, Cheplapharm, Recordati and Covis.
Shaun is a Fellow in Entrepreneurship at Cambridge University Judge Business School and is a member of the Board of Cambridge United Football Club, Cambridge Arts Theatre, Healx and Prostate Cancer Research Centre.
Based in Cambridge, Shaun enjoys rugby and soccer, and occasionally turns his hand to sports writing.